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Abstract
Our study sought to explore the actual and potential roles of patients, physicians, and pharmacists, 
as well as their shared challenges and opportunities, in improving the safety of medication use 
during pregnancy. We conducted virtual focus groups with 48 women and in-depth interviews with 
nine physicians and five pharmacists. Qualitative analysis revealed that all three groups of 
participants reported “playing it safe,” the need for an engaged patient making informed decisions, 
challenges surrounding communication about pregnancy status, and a lack of patient-centric 
resources. Patients, physicians, and pharmacists are highly motivated to protect developing babies 
from potential harms of medication use during pregnancy while maintaining the patient’s health. 
Strategic messaging could maximize the effectiveness of these interactions by helping physicians 
discuss the benefits and risks of medication use during pregnancy, pharmacists screen for 
pregnancy and counsel on medication safety, and patients using medications to share pregnancy 
intentions with their providers pre-pregnancy.
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Medication use during pregnancy is becoming more common, and its impact on maternal 
and fetal health is a growing concern in the public health and clinical care arenas. Recent 
studies have shown that most pregnant women across developed countries took at least one 
medication during pregnancy (Lupattelli et al., 2014; Mitchell et al., 2011). One of these 
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studies also showed that 70% of women in the United States took at least one medication 
during the first trimester (Mitchell et al., 2011).
Because pregnant women are not routinely included in premarketing medication studies, 
information about medication safety during pregnancy is limited. More than 90% of the 
medications approved by the U.S. Food & Drug Administration (FDA) between 1980 and 
2010 that were examined in a study had an undetermined teratogenic risk (Adam, Polifka, & 
Friedman, 2011). Nonetheless, some medications have been associated with adverse 
pregnancy outcomes when taken during pregnancy (Briggs, Freeman, & Yaffe, 2008), and it 
is generally accepted that certain medications can cause serious birth defects if taken during 
pregnancy (Fisher, Rose, & Carey, 2008; Obican & Scialli, 2011).
The limited availability of information on medication safety during pregnancy underscores 
the important role that health care providers play as trusted sources of information for 
women. Of the obstetrician-gynecologists (OB/GYNs) responding to a survey assessing 
knowledge and resources about the risks of medication use during pregnancy, 90% reported 
receiving questions from all or many of their pregnant patients about the effects of 
prescription medication on the fetus; 63% reported that all or many patients had inquired 
about the fetal effects of over-the-counter medications (M. A. Morgan, Cragan, Goldenberg, 
Rasmussen, & Schulkin, 2010). OB/GYNs are not the only health care providers who are 
discussing safe medication use during pregnancy; on the contrary, other types of health care 
providers including pharmacists are receiving questions from patients regarding drug safety 
during pregnancy (Crijns et al., 2013; Eisenberg, Stika, Desai, Baker, & Yost, 2010; 
Goodwin, Rieder, Rieder, & Matsui, 2007; Schwarz et al., 2009). Women of childbearing 
age commonly believe that health care providers should be responsible for initiating 
conversations about the risks of medication (Santucci, Gold, Akers, Borrero, & Schwarz, 
2010). For such conversations to be effective, participants indicated that they should include 
reasoning for the health care providers’ inquiry about family planning and cover (with 
repetition) timely, comprehensive, and clear information regarding a medication’s potential 
effect on a fetus. Although research is limited on whether and how much health care 
providers share information about medication use, evidence suggests that health care 
providers do not provide contraceptive counseling to the majority of women of childbearing 
age to whom they prescribe possibly teratogenic medications (Schwarz, Maselli, Norton, & 
Gonzales, 2005; Schwarz et al., 2012; Schwarz et al., 2013; Schwarz, Postlethwaite, Hung, 
& Armstrong, 2007). Barriers for care providers include the perception that they have not 
been taught to recognize which medications are known teratogens (Eisenberg et al., 2010), 
liability concerns, difficulty interpreting and communicating information for patients in an 
understandable way, insufficient time to communicate information to patients, and concerns 
about how patients’ anxiety about risks will affect their decisions to use necessary 
medications (M. A. Morgan et al., 2010; Schwarz et al., 2009).
Pharmacists also play a critical role in medication safety for pregnant women. Pharmacists 
are easily accessible and are available for consultation at the point of medication dispensing 
(Damase-Michel, Christaud, Berrebi, Lacroix, & Montastruc, 2009; Samuel & Einarson, 
2011). Some literature has shown that pharmacists feel ill-equipped to provide guidance to 
pregnant women about medication use, are not aware of resources specific to counsel 
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pregnant women, and often refer the patient back to the prescribing physician without 
providing consultation (Samuel & Einarson, 2011).
Finally, women also face challenges in patient–provider interactions and decision making 
around medication use during pregnancy. The increased medicalization of pregnancy and 
surveillance for a multitude of risks has affected how women interact with the health care 
system and make decisions for the health of their fetus (Hammer & Burton-Jeangros, 2013). 
In addition, an increased focus on the fetus as a protected entity in society in combination 
with pervasive societal perceptions of a pregnant woman’s role as caring and monitoring her 
body for the protection of the fetus further affects women’s interactions with providers and 
decisions around medication use (Lupton, 2012). These cultural trends have shifted the 
emphasis from the pregnant woman as the primary patient to the health of the fetus, above 
all. For example, in one study about insulin use to treat gestational diabetes, women reported 
feeling a “loss of control” over decisions in their care, and perceived the use of “scare 
tactics” in interactions with providers (Figueroa Gray, Hsu, Kiel, & Dublin, 2017).
The interactions between a woman, her physicians, and her pharmacist have the potential to 
influence her use of prescription and over-the-counter medications during pregnancy, yet 
barriers exist to these interactions. A 2015 expert panel convened by maternal and child 
health leaders in the United States highlighted a research gap and the need for specific 
approaches to improve patient–provider communication around the risks of medication use 
and improved, shared decision making (Riley, Cahill, Beigi, Savich, & Saade, 2016). To 
address this gap, we conducted formative research with each of these three groups—patients, 
physicians, and pharmacists—to learn more about their knowledge, attitudes, behaviors, and 
decision-making processes that factor into these interactions, as well as their access to 
information and resources about medication safety during pregnancy.
The primary aim of the exploratory study reported in this article was to triangulate the 
findings from formative research across these three participant groups to develop 
understanding of the potential and actual roles of each group as well as their shared 
challenges and opportunities in improving medication safety during pregnancy.
Method
Literature Review
At the outset, our partners at the March of Dimes Foundation conducted a literature search in 
PubMed that identified a total of 37 peer-reviewed articles published in English between 
2004 and 2014, which were subsequently retrieved, reviewed, abstracted, and summarized. 
The knowledge gaps identified through the literature review led us to select qualitative 
methods—specifically focus groups and in-depth interviews—as it was apparent to us that 
filling them would require a level of detail in responses that is difficult to achieve via large 
surveys, especially without evidence to guide the development of response categories (D. 
Morgan, 1998). The literature review findings informed our selection of women, physicians, 
and pharmacists as participants as well as our segmentation design within each of these three 
participant groups. Finally, the literature review findings facilitated our development of an 
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assortment of research questions to guide our data collection with each participant group; 
examples of specific research questions by group are shown in Table 1.
Participants and Procedures
In 2014 to 2015, we conducted interviews with nine physicians and five pharmacists, as well 
as six virtual focus groups with 48 women who took medication while pregnant or planning 
a pregnancy. All interviews and focus groups were conducted in English within the United 
States. All participants were recruited by a professional recruitment firm that provides 
tailored recruitment by using their proprietary online panels and following up with telephone 
recruiting. The recruiter used screening questionnaires developed by the study team to 
identify eligible participants representing a mix of selected characteristics (i.e., provider 
specialty, geographic region, demographics). Participants received a monetary incentive as a 
thank you for their time.
Physician and pharmacist interviews—We obtained a purposive sample of physicians 
who had been practicing medicine for at least 2 years and who had prescribed medications to 
a woman of reproductive age in the past 3 months. The sample included three general 
practitioners or family medicine doctors, three psychiatrists, and three allergists or 
pulmonologists. These specialties were chosen because those providers often treat 
conditions common to women of childbearing age that frequently require prescriptions for 
condition management. However, these specialists may lack the awareness of issues of 
medication safety in pregnancy and may be less comfortable speaking about them with 
patients (in contrast to OB/GYNs and other health care providers who regularly see pregnant 
women). We obtained a purposive sample of licensed pharmacists who had been practicing 
for at least 2 years, and who reported providing medication counseling to patients at least 20 
hours per week in a retail setting. A trained interviewer conducted each interview via 
telephone using a semistructured interview guide. The interviews were audio-recorded, and a 
notetaker recorded key responses. Each interview lasted approximately 45 minutes and was 
professionally transcribed.
Patient virtual focus groups and interviews—We conducted six virtual focus groups 
with women (18–44 years old) in the United States. The use of virtual focus groups, in lieu 
of traditional focus groups, offered important benefits to the study, including giving 
participants more privacy and anonymity, which we believed may be important to women 
with chronic or acute conditions or who may perceive taking medication during pregnancy 
as a sensitive topic. To capture different perspectives on and experiences with medication 
use during pregnancy, the virtual focus groups were segmented by pregnancy status and 
medication type (see Table 2).
A trained moderator used a semistructured moderator guide to lead participants in an open 
discussion. We partnered with an online focus group vendor to conduct realtime, live-chat 
sessions, which allowed the moderator to post questions and probes and allowed participants 
to type responses visible to the moderator and all other participants. Each group lasted about 
60 to 90 minutes, and transcripts were produced instantaneously.
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To supplement the virtual focus groups and obtain a more in-depth perspective on themes 
identified in the focus groups, we conducted follow-up telephone interviews with a subset of 
participants. We selected two participants from each focus group who provided an 
interesting perspective or exemplified a major focus group finding and invited these women 
to participate in one-on-one telephone follow-up interviews. All 12 invited participants 
agreed to participate in the follow-up calls. Each interview lasted approximately 20 to 30 
minutes.
Ethical Issues
All data collection was approved by RTI International’s Institutional Review Board. In 
accordance with the Paperwork Reduction Act, data collection with women was approved by 
the Office of Management and Budget. All participants consented prior to participation in 
data collection. Specifically, for virtual focus groups, participants were invited into a virtual 
waiting room prior to the start of each live-chat session where the moderator posted the 
informed consent form, which described the purpose of the study; informed participants that 
their participation is voluntary; and informed them that their identity and anything they say 
will be treated in a secure manner and will not be disclosed, unless otherwise compelled by 
law. If willing to participate, participants checked a box indicating their consent that then 
linked them into the live-chat session. The same information was provided to telephone 
interview participants as part of obtaining their verbal consent prior to beginning the 
interview. All participants had the option of refusing to answer any questions or terminating 
their involvement in the study at any time, without penalty.
Data Analysis
A crux of our analytic methodology was using triangulation between the three groups to 
develop an understanding of the roles each group plays in medication safety, as well as the 
barriers and facilitators to safer medication use. As a single source would not be able to 
elucidate the complete picture, we utilized multiple data sources to enrich our understanding 
of the problem and potential solutions (Denzin, 1978). To conduct this triangulated analysis, 
two analysts independently reviewed and coded transcripts in NVivo 10.0 qualitative 
analysis software. Analysts coded responses according to a set of predetermined codes 
representing key constructs from the research questions and developed and assigned 
emergent codes for responses that did not fit the preexisting coding scheme (Krueger & 
Casey, 2000). To determine interrater reliability, the analysts double coded the first two 
transcripts from each set to ensure that the data were coded consistently. Coders compared 
and reconciled differences. Subsequent to reaching agreement of 90% and above, transcripts 
were coded by one analyst. Coding reports were produced, and key themes and trends across 
the virtual focus groups and interviews, participant groups, and, when applicable, specific 
segments of the participants were identified. The degree of consensus or discordance with 
particular views was assessed to focus on what the group, rather than individual, thought. 
After key themes were independently identified for each participant group, the research team 
examined overlapping themes between the three participant groups to triangulate findings 
and identify the most salient themes across all three groups. Per Krueger and Casey’s (2000) 
recommendations, we also examined the extent to which what we knew and what we 
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suspected was confirmed or challenged by our data as well as what we observed that was 
new and not previously suspected.
Results
Sample Characteristics
Physicians—The nine physicians interviewed practiced in seven different U.S. states. Six 
were male and three were female. The majority of the physicians (n = 7) had been practicing 
for more than 10 years post-residency. The physicians worked in a variety of health care 
settings including community health centers, hospitals, small group practices, or offices 
specific to their specialty.
Pharmacists—The five pharmacists interviewed resided in five different U.S. states and 
all were male. The majority of the pharmacists (n = 4) had been practicing for more than 10 
years and their experience ranged from 4 years to 35 years of pharmacy practice. All of the 
pharmacists worked in retail settings, and two mentioned working in both retail and hospital 
settings.
Patients—As shown in supplemental table, the participants ranged in age from 23 to 44 
years. The majority of participants were White (54%), reported a total family income in the 
US$30,000 to US$75,000 range (52%), and had completed some college education (from 1 
to 4 years; 83%). The focus groups included participants from across the United States.
Findings
In this section, we present intersecting themes that emerged from interviews and focus 
groups with the three participant groups.
“Play it safe. ”—All three participant groups indicated that the safety of the mother and 
fetus was the top priority in making decisions about medication use during pregnancy, 
although patients tended to focus more heavily on the safety of the fetus. When prescribing 
or dispensing medication to pregnant women, physicians and pharmacists choose the safest 
treatment approach possible during pregnancy for the mother and fetus.
Not surprisingly (Wiley, Cooper, Wood, & Leask, 2015) women reported that they are 
cautious in their use of medication during pregnancy and are highly motivated to protect 
their babies. Most women reported that they would not take medication during pregnancy if 
risks to the fetus are unknown or if there is conflicting information about potential serious 
risks to the fetus. For example, one participant explained, “If there’s no risk information, 
then I don’t take the medication. It’s not worth risking the little one. I’d value my doctor’s 
opinion, but I don’t want to cause life-long damage to the baby.” Similarly, another woman 
indicated that “I would never take a medication without being very clear on possible side 
effects for my baby, and if it’s some newer medication without much feedback information 
other than clinical trials, I would probably not take it.” Women who reported less severe 
conditions, particularly those with mild/moderate depression, spoke of using alternative or 
homeopathic medications or therapies to replace their prescribed medications. As one 
interview participant who was taking medication for depression made a comment that was 
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representative of women’s focus on the safety of the fetus said, “If I have any doubts about 
something, there is probably some reason behind it. Rather than gambling, why not just play 
it safe? It’s more about focusing on the baby’s health.”
Physicians said they strive to provide the safest management of medication for pregnant 
women. This management may involve tapering patients off a drug (a known teratogen), 
ramping up a drug (e.g., if it prevents an acute episode during pregnancy), or switching to a 
different drug (e.g., with more data about its use and effects during pregnancy). As one 
allergist explained,
Less is more. I try to do the most benign treatments, nasal saline irrigation and 
maybe a first-generation, over-the-counter antihistamine that’s [FDA] Category B 
[no risks identified for the fetus based on animal studies] or an intranasal steroid 
that’s category B. If they’re comfortable enough just with the saline rinse, that’s 
what I suggest during the first trimester.
Pharmacists were also cautious when filling and discussing prescriptions with pregnant 
women. Pharmacists perceived their role as critical for double checking what physicians 
prescribe. One pharmacist explained,
I see myself as the safety monitor for the patient and to make sure that when the 
patient is taking those medications … they should be safe for her and if there is 
concern I will make sure that she knows about it. If there’s some significant danger 
to her or to the fetus I will contact the patient directly.
An engaged patient—All three participant groups described the need for an active, 
engaged patient to participate in the decision-making process.
In many cases, women said they were the ones to initiate discussions with providers about 
medication use in pregnancy and that they were left to educate themselves about the risks 
and benefits of the medications. Women trusted their OB/GYNs and looked to them as good 
resources; nevertheless, the women in our study believed that making the final decisions was 
up to them. For example, one interview participant taking medication for depression said,
What’s funny is I just saw [my doctor], and after the fact, I was surprised she didn’t 
bring it up although I didn’t bring it up either. I should probably call and ask. I 
think it would probably be better to reduce [my dosage] before I become pregnant.
Many women noted that initiating discussions with their physicians, doing their own 
research, and making complex decisions about medication use during pregnancy were, in the 
end, their responsibility.
Because making decisions about the risks and benefits of medication use is complex, 
physicians reported talking through decisions with their patients so that each patient could 
make the best decision for her situation. One physician explained the importance of 
collaborative decision making:
In general, just again, very collaborative, so that’s the way the philosophy of the 
clinic has been because there’s a lot of patient interaction … They’re more 
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involved. That seems to work out better, better compliance with them being more 
interactive in the whole process. So it gives them more control.
Pharmacists reported that their role was to provide information about the potential risks of 
specific medications during pregnancy and to encourage patients to speak with their 
physicians. Although pharmacists provide information about medications’ potential risks, 
they believe the patient should consult her physician to discuss the risks and benefits of her 
treatment plan. One pharmacist said,
Most of the time I tell them they should ask their doctor before they take anything 
… If it’s a drug that I know is fine, then I will tell them it is fine. If it is borderline, 
I’d say, “I wouldn’t take it until you can talk to your doctor.”
Patient/provider communication about pregnancy status—All three participant 
groups described that, ideally, women, their prescribing physicians, and the dispensing 
pharmacists should be aware of the patient’s pregnancy status or intention to become 
pregnant, and discuss the best course of treatment based on that status. However, the 
participants reported challenges in the practicality of this approach.
Many women viewed the time prior to pregnancy as the optimal time to develop a treatment 
plan, but few were actually talking to their physicians in the preconception period.
Although women said that they would like to begin discussions with their physicians prior to 
pregnancy and discontinue medication or change dosages before becoming pregnant, in 
actuality, many reported they would not have these discussions until they find out they are 
pregnant. One woman planning a pregnancy said,
I think about it all the time and I have just told myself as soon as I know I am 
pregnant will be the time I stop my medication. I do plan on having open 
communication about everything with my OB/GYN and if I have problems [I’m] 
hoping that they can help suggest something.
Physicians reported that they ask about a patient’s pregnancy status at the time that they 
prescribe the medication. Some physicians screen their patients for pregnancy or pregnancy 
intention and factor this in when prescribing potential teratogens. However, the physicians 
we interviewed reported a low percentage of pregnant patients in their practices. Although 
our sample may not be generalizable, it is important to note that some specialists may not 
frequently treat pregnant women or that the physicians’ awareness of pregnancy status 
among their patients may be low.
Most pharmacists reported that there is not a standard method of assessing pregnancy status 
or intention if the patient does not disclose her status. Furthermore, some pharmacists 
reported being uncomfortable asking a woman her pregnancy status directly during a routine 
interaction. Many of the pharmacists interviewed indicated that their pharmacy computer 
systems do not have a systematic way of tracking pregnancy status, and especially of 
tracking pregnancy intention.
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Lack of patient-centric educational materials—In general, women reported wanting 
more specific information from multiple sources about potential harm to the baby so they 
could make the best decisions based on all the available information. Overwhelmingly, 
women reported that their OB/GYNs were trusted sources of expert opinion and 
recommendations about medication use during pregnancy. Patients seemed most interested 
in having as much detailed information as possible on the risks associated with medication 
use during pregnancy. As one woman planning a pregnancy explained,
I wish my doctor would give me information or a print-out with all of the 
information so I’d know about all the possible side effects. I’ve asked him this 
before but he’s always rushed … I want him to tell me all the possible side effects 
in the long run, not just for my child but for me too.
However, when counseling pregnant women about the risks and benefits of a medication, 
many physicians reported sharing materials with patients that were meant for clinicians with 
no translation for lay audiences. In general, physicians mentioned FDA categories as the 
major indicator of a drug’s safety during pregnancy, not only relying on them for their own 
information but also using them in an attempt to help patients understand risks. In the 
interest of giving patients all the available information, several providers commented that 
they will give information that they receive about a drug directly to their patients, even if the 
resource is targeted to physicians and may be difficult for patients to interpret.
When dispensing medications to pregnant women, pharmacists reported printing a handout 
with information, either from the drug manufacturer’s website or the pharmacy’s 
information system, to aid verbal counseling. Two pharmacists mentioned that they did not 
distribute any educational materials about a drug besides the package insert.
Discussion
Ultimately, patients, their physicians, and their pharmacists should share responsibility for 
ensuring medication safety during pregnancy. Maternal and fetal health could be endangered 
if the members of any or all of these three participant groups rely too heavily on the others to 
make sure that risks are identified, communicated, and carefully balanced with benefits 
before usage. For example, safety could be compromised if a physician relies on his or her 
patient to proactively mention that she is planning a pregnancy and the patient does not 
initiate the conversation because she does not realize that her medication might be 
teratogenic. Similarly, harm could result if a specialist who commonly prescribes 
medications to women of childbearing age does not screen for pregnancy status and the 
patient’s pharmacist assumes that the physician would not have prescribed the medication if 
the women were pregnant. Avoiding these kinds of issues with diffusion of responsibility 
will require a concerted, collaborative effort on the part of all three groups of participants.
Findings from this study support and expand upon previous literature. Previous research 
exploring patient–provider communication about medication safety during pregnancy 
elucidated barriers facing patients, physicians, and pharmacists (Eisenberg et al., 2010; 
Figueroa Gray et al., 2017; Hammer & Burton-Jeangros, 2013; M. A. Morgan et al., 2010; 
Obican & Scialli, 2011; Santucci et al., 2010; Schwarz et al., 2009). Our exploratory study 
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delved deeper into some of those barriers, with special attention to identifying shared 
challenges affecting the interactions of these three participant groups. Fortunately, we found 
that, despite the barriers to doing so, patients, physicians, and pharmacists are highly 
motivated to increase medication safety during pregnancy. However, that motivation needs to 
be coupled with careful planning; coordination; and access to effective informational 
resources to yield the desired outcome.
By working together to develop a treatment plan prior to pregnancy, patients and their 
physicians can ensure that there is adequate time to consider potential benefits and risks and 
to engage other providers in the decision-making process as appropriate. Technology can be 
harnessed to facilitate coordination across the health care team. For example, by 
systematically documenting pregnancy status (including planning or intention to become 
pregnant) and the medication-related decision-making processes in electronic health records 
and pharmacy information systems, physicians and pharmacists can more easily ensure that 
medications are being prescribed and dispensed in the safest manner possible. The quality 
and utility of the information being used in these critical decisions about medication use 
during pregnancy is paramount; physicians and pharmacists must have access to 
comprehensive resources that meet their clinical needs as well as easily understandable 
resources for patients so that they can work as partners to make the best decisions.
Finally, we learned that health care providers have been not only relying on the FDA 
pregnancy categories to inform their own understandings of medication risks but also using 
them to inform patients’ decision making despite potential difficulties that both groups may 
face in interpreting this information. Of note, during the process of our formative research, 
the FDA announced longawaited changes to pregnancy and lactation labeling regulations for 
prescription medications and biological products (FDA, 2016). Years of criticism of the 
letter categories had revealed them to be overly simplistic and often misinterpreted as a 
gradation of risk rather than as an accounting of the balance of risk and benefit, as they were 
originally intended (Kweder, 2008). The discontinuation of these letter categories (occurring 
in a phased approach over several years; FDA, 2016) will require physicians to adapt to a 
new label format and determine how best to relay this content when counseling their 
patients.
Practice Implications
As emphasized in the 2015 expert panel (Riley et al., 2016), there is a major research gap 
around specific approaches to improve patient–provider communication about risks of 
medication use. Based on our research, we present suggestions for strategic messaging to all 
three participant groups from this study. For patients, we suggest developing messages 
alerting women of childbearing age to the importance of starting the process of becoming 
informed about the safety of medication use during pregnancy prior to conception. These 
messages should empower women by encouraging them to speak with their health care 
providers in addition to consulting reputable sources (e.g., patient information inserts 
provided with medications) independently to learn about the potential risks of medications 
they are currently taking. We also suggest messaging that encourages women who are 
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pregnant or could become pregnant to consistently communicate their pregnancy status and 
plans to their health care team.
For physicians, we suggest developing messages to prompt them to talk with patients about 
the risks of taking, stopping, or changing the dosage of a medication while trying to become 
pregnant or during pregnancy. Given that many pregnancies are unplanned, we also strongly 
suggest the development of reminders geared at prompting all provider types (i.e., not just 
OB/GYNs) to discuss issues around medication use during pregnancy with their patients of 
childbearing age. In addition, we suggest the development of digital applications for 
providers that include links to patient-centric resources that can be printed, emailed, or sent 
by text messaging.
Finally, we have suggestions that would help better integrate pharmacists in efforts to 
improve medication safety. First, we suggest the development of marketing materials and 
journal publications highlighting the unique and critical role that pharmacists play in 
medication safety during pregnancy. Second, pharmacists in the retail setting need to be 
encouraged to take a more active role in screening for pregnancy and advising patients on 
medication safety both before and during pregnancy. It is important to address the issue 
interviewees raised about the lack of a systematic way of tracking pregnancy status (e.g., 
planning a pregnancy, woman of childbearing age—pregnancy status unknown, lactating) in 
pharmacy computer systems; we suggest working with retail pharmacy chains and pharmacy 
information system developers to include more options for assessing and documenting 
pregnancy status. For example, automated telephone systems for refill requests could be 
programmed to ask all callers whether they are pregnant and if so, how many weeks 
gestation. Patients’ responses would be added to the pharmacy information system and 
flagged to ensure that an alert is generated prompting a pharmacist to speak with the patient 
about a medication’s risks during pregnancy when they pick up the prescription.
Limitations
The uniqueness of this study is that it triangulated findings between three significant groups 
involved in medication safety during pregnancy: women, prescribing physicians, and 
pharmacists. Although the study was strengthened by the triangulation of findings between 
the three participant groups, the study also faced some limitations. We acknowledge that our 
sample size was small. The patients included in our purposive sample may not be 
representative of the larger U.S. population of women of childbearing age in terms of 
geography and demographic characteristics (e.g., education, income, race), and the types of 
providers we included are not representative of the universe of health care providers 
involved in caring for women of childbearing age. Along similar lines, the physicians we 
interviewed reported that a low proportion of their patient loads were pregnant, meaning that 
we were asking them to focus on interactions that they have infrequently and/or perceive as 
infrequent. Also, the pharmacists we interviewed were all males; it is possible that female 
pharmacists would have different responses. Future research with a larger, more 
representative sample could be used to understand how widespread these challenges and 
opportunities are.
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Conclusion
Patients, physicians, and pharmacists are highly motivated to protect fetuses from the 
potential harms of medication use during pregnancy. The interactions women of 
childbearing age have with their physicians and pharmacists have the potential to influence 
the decisions they make about medication use. Strategic messaging and improved 
informational resources could help maximize the effectiveness of these interactions by 
ensuring that women receive the clear, credible, and comprehensive information about 
medication risks during pregnancy at the right time and in a manner that facilitates the safest 
possible management of their health conditions.
Physicians need messaging to facilitate their discussion about medication use in pregnancy 
with women of childbearing age. Pharmacists need messaging that empowers them to play a 
more active role in screening for pregnancy and counseling women of childbearing age. 
Both physicians and pharmacists need improved informational resources to support their 
interactions with patients. Finally, women need messaging to promote the importance of 
sharing pregnancy status/intention with their providers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Selected Formative Research Questions by Participant Group.
Women Physicians Pharmacists
• How does having a chronic 
or acute condition influence 
women’s knowledge, 
attitudes, and behaviors 
regarding medication use 
during preconception and 
pregnancy?
• What messages do pregnant 
women and women of 
childbearing age receive 
from providers and other 
sources?
• How do pregnant women 
and women of childbearing 
age weigh risks and benefits 
of medication use during 
pregnancy, considering both 
the baby’s health and their 
own health?
• Who do women perceive is 
their primary point of 
contact for questions about 
medication use during 
pregnancy?
• What resources and tools are 
health care providers aware of 
and which resources and tools 
do they use? How do these 
resources and tools vary by 
practice type?
• What are the most common 
concerns pregnant women and 
women of childbearing age 
have about medications?
• How do health care providers 
balance the risks and benefits to 
both mother and fetus?
• To what degree are patient 
preferences factored into the 
decision-making process?
• What do health care providers 
perceive as their role in 
counseling/prescribing/
suggesting effective 
contraception when they 
prescribe possible teratogens?
• Do health care providers screen 
for intention to become 
pregnant when prescribing 
possible teratogens?
• What role do pharmacists play in 
counseling pregnant women and 
women of childbearing age about 
drug safety, including risks and 
benefits of medication use?
• How are pharmacists increasing 
drug safety for pregnant women 
and women of childbearing age?
• What protocols and information 
systems do pharmacists have in 
place to screen for teratogenic 
risks?
• How often are pharmacists asked 
about the risks of a medication if 
the customer should become 
pregnant or if she is pregnant?
• Does communication between 
providers and pharmacists change 
with pregnant women and women 
of childbearing age when 
prescribing possible teratogens?
• How do pharmacists 
communicate back to physicians 
after dispensing or counseling?
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Table 2
Virtual Focus Group Segmentation (n = 6 Virtual Focus Groups).
Pregnancy Status Group No. Prescription Medication Type
Women aged 18–44 planning to become pregnant in next 1–2 years who … 1 Currently take medication for chronic pain
2 Currently take an antidepressant
3 Currently use an asthma medication
Women aged 18–44 who gave birth within the last year who … 4 Took a short-term medication during pregnancy
5 Took an antidepressant during pregnancy
6 Used an asthma medication during pregnancy
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